Hypoxia-inducible factor 2α (HIF-2α) is a transcription factor that plays a key role in oxygen homeostasis and response to tumor hypoxic microenvironment of cancer cells. Previous research has suggested that inhibition of HIF-2α is a promising antitumor approach, particularly against tumors associated with mutant von Hippel-Lindau (pVHL).
Researchers from Jinan University (Guangdong) and affiliated organizations reported new data detailing the discovery and preclinical characterization of novel fibroblast growth factor receptor 4 (FGFR4) inhibitors for the treatment of hepatocellular carcinoma (HCC).
Hepatocellular carcinoma (HCC) is a complex disease where both the activation of the cyclic GMP-AMP synthase-stimulator of the interferon gene (cGAS-STING) pathway and the induction of immunogenic cell death (ICD) have proven effective immunotherapeutic strategies in some instances.
South China University of Technology and affiliated organizations have published data from a study that aimed to assess the role of the recently identified human hexokinase, hexokinase domain component 1 (HKDC1), in regulating tumor immune cell response in hepatocellular carcinoma (HCC).
Researchers from Sun Yat-Sen University and MD Anderson Cancer Center have compared the proteins secreted by hepatocellular carcinoma (HCC) cells in responders and nonresponders to the anti-PD-1 antibody nivolumab.
Myc proto-oncogene protein (MYC) is a transcription factor that can modulate the transcription of several genes, and its overexpression has been found in many cancer types, including hepatocellular carcinoma (HCC). Its inhibition reverses tumorigenesis in vivo and it is a key therapeutic target in cancer. Stanford University scientists used CRISPR screening assays to identify several genes as downstream targets of MYC, including exportin-1 (XPO1), among others.
Researchers from Sirnaomics Inc. presented preclinical evaluation of novel intravenous polypeptide nanoparticle designed to simultaneously deliver two siRNAs, silencing TGF-β and COX-2.
Hepatocellular carcinoma (HCC) is characterized by a high rate of neovascularization, giving tumoral cells access to nutrients and contributing to disease progression and metastasis.
Therabionic GmbH received U.S. FDA humanitarian device exemption (HDE) for its P1 device for at-home treatment of hepatocellular carcinoma, which accounts for 80% of all liver cancers, in patients who have failed first- and second-line therapies.